RPGLIFENSE29 July 2023

RPG Life Sciences Limited has informed the Exchange about Investor Presentation

RPG Life Sciences Limited

RPG LIFE SCIENCES

July 29, 2023

RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127 Email: info@rpglifesciences.com www.rpglifesciences.com CIN : L24232MH2007PLC169354

The Manager Listing Department National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C-1, G- Block, Bandra - Kurla Complex, Bandra (East) Mumbai — 400 051

BSE Limited

Corporate Relationship Department

25, P.J. Towers,

Dalal Street, Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

Sub: Investor Presentation

Please find enclosed herewith a copy of Investor Presentation with respect to Unaudited

Financial Results of the Company for the quarter ended June 30, 2023.

Kindly take the same on record.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited RAJESH RAMESH rivestshranieiar ilg«;ﬂzfnzzaugwaaasg SHIRAMBEKAR

ned by

lly

Rajesh Shirambekar Head — Legal & Company Secretar

Encl: As above

An ®RPG Company

RPG LIFE SCIENCES

An ~>>R,::.c:; Company

Investors’ Presentation Q1 FY24

Disclaimer

This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.

The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the “Company”), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

An <l>» RPCi Company

R?G LIFE SCIENCES

RPG Group: One of India's fastest-growing diversified conglomerates

UN -EA,SHTALENT TOUCH LIVES 1QIUTPERF 10RM AND,@

RPG Group has a business history dating back to 1820 AD in banking, textiles, jute, and tea. RPG Enterprises was founded in 1979 and currently operates in various businesses in Infrastructure, Technology, Tyres, Life Sciences, and plantation industries. Formerly known as Searle India, RPG Life Sciences was started as a joint venture with G.D Searle in 1968 and was rechristened to RPG Life Sciences in 1999 with G.D Searle withdrawing its India operations.

100+ years old Business Group |

$4.4 Bn Revenue |

20000+ Employees |

BSE Listed Companies

One of India’s leading tyre Manufacturers

EPC major in infrastructure segments like T&D, Civil, Railways, Oil & Gas

__,,,,,, ZenSar Global Technology Consulting and IT services company

R?G LIFE SCIENCES

An Integrated Pharmaceutical company operating in Formulations and Synthetic APIs

Raychem ·RPG

Technology Solutions company catering to energy and infrastructure

An <l>» RPCi Company - - - - - - - - - - - - - - - - - - -

HARR/SONS MALAYALAM LIMITED

One of India’s largest plantation companies producing tea, rubber etc

R?G LIFE SCIENCES

RPG Life Sciences: An Integrated Pharmaceutical Company –APIs to Formulations; R&D to Manufacturing to Marketing

RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.

Domestic Formulations (DF)

Develop, manufacture and market branded formulations in India & Nepal

APIs 15%

International Formulations (IF) 19%

Domestic Formulations (DF) 66%

International Formulations (IF)

Develop, manufacture and sell oral solid dosage formulations in the generics and branded generics space across regulated and emerging markets

APIs

Develop, manufacture and sell high value synthetic APIs in the general therapeutic category

An <l>» RPCi Company

Leader in Immunosuppressants

10+ Therapies represented by High Equity brands

50+ Markets Presence

3 Manufacturing Facilities

1200+ Employees

R?G LIFE SCIENCES

RPG Life Sciences Product Portfolio: Strong ‘Textbook’ brands being augmented by Diligent Life Cycle Management and New Launches in Chronic and Specialty therapies

Domestic Formulations (DF)

Key Therapies

Nephrology

Rheumatology

Oncology

Pain Management

Gastroenterology

Neuropsychiatry

Cardiovascular

Diabetes

Urology

Legacy Portfolio

Immunosuppressants

Text Book Brands

Azoran· Azathioprine

Mycophenolate Mofetil

'Aroimune ME. Cyclosporine

lklmunotac Tacrolimus

Azoran· Azathioprine

Spironolactone • < Lomotil Diphenoxylate HCl 'Nap_rJ,_~yn· Naproxen Serenace Haloperidol

Disopyramide Phosphate

Key Products

Specialty 'HerMab'i T"""'-"••a~1k:r ,·.,, .,..,1~r'!l.'.a.'l ri,r; ~ Trastuzumab

Adlumab·

'·,;:. ,,.11..o.· ~-1 --.-':., ,,_

Adalimumab Ivzumao Bevacizumab

-••b~mabl00"'9/-m,g

~•.

Rituximab

,,,.,aw

Tofacitinib lr(JHigh" Iron Isomaltoside

lronl1DNltotiiltlYillSml(l0Dmglmlj

Denosumab

New Portfolio

Chronic

'NuGliptin Vildagliptin

Gli tiNexf ....... _ Teneligliptin

Dapagliflozin

Azilta·-1& Azelinidipine

·solifirsf Solifenacin

~S...:.,.,,,151 1""9

Life Cycle Management (Existing Products) Azoran7s

AZathiol>l'ino 75 fl>!I Tol>w

'Alrl~rfnno.': T ~ ~ •:my Aldactone· la

SpirooolKtone 50mg + Frusemicle ZDm,g

·Naprosyn'::: +

...., ..... $< .... ...... ,"',;,, ;:,<_,,,;,;,..,

'ROMILAST:BL

1;;,..,,!JK"':f•lmrl:<l'lrl,"1,tj:'6e<j:M"".J ,..i~-.,.,;. !,.,,..,.,;,.r . ......,, More Smart ••• More EfflcientJ

International Formulations (IF)

Key Products Generics - Azathioprine, Sodium Valproate PR, Nicorandil, Sertraline Branded Generics – Siloxogene, Azoran, Mofetyl, Arpimune ME, Dyzantil, Dipsope

APIs

Key Products APIs - Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole, Diphenoxylate

An <l>» RPCi Company

R?G LIFE SCIENCES

Financial Performance

An <l>» RPCi Company

R?G LIFE SCIENCES

Journey of RPG Life Sciences

Process Excellence Product Portfolio, People, Business Processes

Fundamentals Fixation Sales Hygiene, People, Organization

Sustainable Profitable Growth Revenues, Volumes, Margins

An <l>» RPCi Company

Benchmark Performance Profitability, Leverage, Liquidity Ratios

Scale-up

R?G LIFE SCIENCES

Margins: A Trajectory of y-o-y Expansion despite Market Challenges EBITDA:10.4% (FY19) to 23.0%(Q1 FY24);PBT: 4.6% (FY19) to 20.1%(Q1 FY24);PAT: 3.3% (FY19) to 15.0% (Q1 FY24)

EBITDA% 23.0%

PBT% 20.1%

PAT% 15.0%

20.3%

21.0%

16.6%

17.9%

11.7%

13.2%

18.2%

13.8%

10.3%

15.9%

11.1%

7.7%

9.8%

8.1%

6.2%

6.0%

0.9%

0.5%

0.2%

0.4% 0.4%

0.4%

11.1% 10.4%

8.7%

4.2%

9.3%

4.7%

5.9%

3.9%

4.6%

3.3%

Except FY24 Q1, all other margin numbers are full year numbers

An <l>» RPCi Company

R?G LIFE SCIENCES

Q1 FY24 : Yet Another Strong Quarter

Revenue from Operations

- - - t

128.9

147.8

Q1 FY23

Q1 FY24

PAT & PAT Margin

- - t

18.2

14.1%

22.1

15.0%

EBITDA & EBITDA Margin

(All figures in Rs. Crores except EPS in Rs.)

PBT & PBT Margin

29.1

22.5%

Q1 FY23

34.0

23.0%

•

Q1 FY24

25.1

19.5%

29.8

20.1%

Q1 FY23

Q1 FY24

EPS

-t

13.4

11.0

Figures in circle are Margins An <l>» RPCi Company

Q1 FY23

Q1 FY24

Q1 FY23

Q1 FY24

R?G LIFE SCIENCES

Key Financials’ Trends

- - - t ___ t

Revenue from Operations

EBITDA & EBITDA Margin

512.8

440.2

375.6 389.1

330.2

107.5

89.4

70.8

59.9

147.8

34.4

15.9% 18.2%

20.3%

21.0% 23.0%

10.4%

□

FY19

34.1

□ '

15.1

4.6%

(All figures in Rs. Crores except EPS in Rs.)

PBT & PBT Margin

- - t

91.7

73.2

53.6

41.8

11.1% 13.8%

16.6%

17.9%

29.8

20.1%

FY19

FY20

FY21

FY22

FY23 Q1 FY24

FY20

FY21

FY22

FY23 Q1 FY24

FY19

FY20

FY21

FY22

FY23 Q1 FY24

PAT & PAT Margin

- - t

67.6

51.5

40.0

29.0

10.8

22.1

3.3%

7.7%

10.3%

11.7%

13.2% 15.0%

FY19

FY20

FY21

FY22

FY23 Q1 FY24

6.5

FY19

EPS

-t

40.9

31.1

24.2

17.5

13.4

FY20

FY21

FY22

FY23 Q1 FY24

- L

An <t>» RPCi Company ___________ R?G LIFEsc1ENcEs

Key Ratios (ROCE, ROE, D/E) : A Trajectory of y-o-y uptrend

ROCE%

ROE%

Debt/Equity Ratio

- - l

28.5% 29.7%

24.9%

20.9%

18.5% 20.1%

16.4%

22.0%

0.22

9.7%

6.7%

0.06

FY19

FY20

FY21

FY22

FY23

FY19

FY20

FY21

FY22

FY23

FY19

FY20

Company continues to remain Debt-free

An <l>» RPCi Company

0.01

FY21

0.00

FY22

FY23

R?G LIFE SCIENCES

Business Segment-wise Performance: Q1 FY24

Domestic Formulations (DF)

• Domestic Formulations contributed 66% to total sales of Q1 FY24 • • • New products* contribution improving consistently (currently >20%) on account of new

16% sales growth majorly driven by legacy products Better than market growth

launches in Specialty & Chronic segments and line extensions of legacy products Salesforce productivity improved to >5.0 Lakhs versus 3.4 Lakhs in earlier years

•

International Formulations (IF)

International Formulations contributed 19% to total sales of Q1 FY24 Robust sales growth of 15%

• • • New Products/Customers/Markets contribution continues to improve (currently ~30%)

API

• • Growth of 9% •

API contributed 15% to total sales of Q1 FY24

Continuous thrust on new customer development

*Launched FY19 Onwards

An <l>» RPCi Company

97.4

83.9

Q1 FY23

Q1 FY24

27.8

24.1

Q1 FY23

Q1 FY24

20.9

22.6

Q1 FY23

Q1 FY24

R?G LIFE SCIENCES

RPG Life Sciences ICRA Rating Reaffirmed in FY23

Long term rating reaffirmed at A Short term rating reaffirmed at A1

Outlook on long term rating has been retained as Stable

The rating reaffirmation factors:

 Strong brands in the Indian Pharmaceutical Industry  Considerable improvement in the operating performance on the back of

Improvement in sales hygiene

• • Cost rationalisation measures adopted since FY20

 A robust capital structure and strong coverage indicators based on

• Decline in the company’s debt levels • Healthy cash flows • No major debt-funded capital expenditure (capex)

 Expansion of product portfolio and geographical presence augur well for growth prospects

An <l>» RPCi Company

R?G LIFE SCIENCES

Business Strategy

An <l>» RPCi Company

R?G LIFE SCIENCES

Domestic Formulations (DF)

• Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • • • Good customer coverage - Cardiologists, Diabetologists, Urologists, Nephrologists, Rheumatologists, Oncologists • New Product Launches in new category – Biosimilars as well as Chronic and Specialty segments

Leading Text Book Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace Leading player in Immunosuppressant category

Business Strategy

5 pillars of profitable Domestic business growth

Product portfolio rejuvenation by building Chronic & Specialty portfolio with new launches

Strategic brand assets building through life cycle management (new line extensions, customer segments, disease segments, etc.)

Customer coverage deepening in targeted therapies by expanding field force and deploying digital

Sales force effectiveness augmentation by competencies building and productivity enhancement initiatives

An <l>» RPCi Company

Profitability improvement by Opex control, efficient manufacturing operations, sales hygiene as well as profitable product mix

R?G LIFE SCIENCES

International Formulations (IF) Business: Overview and Strategy

• Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging markets - Canada, UK, Germany, France, Australia, South East Asia, Africa •

Long lasting, impeccable supply track record and business relationship with some of the leading generic players of the world

• High quality and process orientation making us a preferred partner •

Investments in plant upgradation and capacity expansion

Business Strategy

3 pillars of step-wise Global business build up

Build immunosuppressant portfolio

Focus on products with specific/ competitive advantage e.g. -

Products needing Special manufacturing conditions like low RH/Temp Complex generic products Low Competition products

- -

An <l>» RPCi Company

Expand footprints in emerging/select markets like Myanmar, Vietnam, Philippines, Sri Lanka, Egypt, Sudan, Thailand, and South Africa

R?G LIFE SCIENCES

APIs Business: Business Strategy and Way Forward

• High value, low volume, niche APIs • Mature stable molecules •

Provides backward integration to International Formulations business

•

Footprints across geographies - LATAM, Germany, China, South Korea, Iran, Bangladesh, Egypt, India, etc. Strong customer focus – long-lasting relationship with big pharma and leading generic firms.

Business Strategy

Business continuity

Market/Customer Expansion (Existing Products)

Pipeline of Niche Product/Portfolio : - -

Immuno-suppressants Limited Competition products Backward integration of IF/DF

An <l>» RPCi Company

State-of-Art, EU/TGA approved Plant with enhanced capacity

R?G LIFE SCIENCES

Infrastructure & Backend Capabilities

An <l>» RPCi Company

R?G LIFE SCIENCES

Manufacturing Facilities

Formulations Unit 1, Ankleshwar

Formulations Unit 2, Ankleshwar

F1 unit caters to the domestic and emerging markets

• • Multipurpose plant with dedicated product lines for oral dosage forms including tablets,

liquids and powder

• WHO, Kenya, Nigeria approved

F2 unit caters to the regulated markets

• • Dedicated product lines for oral dosage (capsules & tablets) • • WHO, EUGMP (from Hamburg Health authority), Canada, Ethiopia, Kenya, Sudan,

Equipped to handle low RH and low temperature conditions products

Nigeria approved

API Unit, Navi Mumbai

• MF1: Multipurpose unit catering to emerging markets including India • MF2: Dedicated immunosuppressant facility catering to regulated and emerging markets

including India

• MF3: Multipurpose unit catering to regulated and emerging markets including India • WHO, PMDA Japan,TGA Australia approved & Written Confirmation (WC) received from

An <l>» RPCi Company

CDSCO

R?G LIFE SCIENCES

Strong Backend Capabilities

Quality

• All critical SOPs harmonized through CQA • Quarterly internal audit of all plants by CQA • All critical deviations, change controls and market

complaints investigation approved by CQA

Regulatory

• Well established & evolved Regulatory function catering to Canada, UK, EU, Australia and emerging markets Expertise of eCTD submissions Integrated project management activities

• •

•

Formulations R&D In addition to Formulations Development of IR, have capabilities to develop modified release & complex generics

• Dossiers gap analysis and fulfilment Tech transfer/site transfer activities • • GLP compliant analytical lab for Development and

Validation of Analytical Methods

Digitalisation Focus Areas

• Quality Management systems : e-QMS, e-DMS, e-LMS. • Access to critical manufacturing equipment through IRIS

scanner

• All QC instruments attached with dedicated software

and server

• All stability chambers with software control •

Secondary packing Complies with EUFMD requirement for Track and Trace.

An <l>» RPCi Company

R?G LIFE SCIENCES

Operational Highlights

An <l>» RPCi Company

R?G LIFE SCIENCES

Top 10 Operational Highlights

Comprehensive Life Cycle Management Strategy for DF Legacy products yielding results

Legacy product Naprosyn becomes the first 60 Cr+ Brand in FY23; Crosses 19 Cr Mark in FY24 Q1

New Product portfolio across identified segments contributing healthy double-digit growth

The new product Denosumab Sales ~5 Cr in the very first year of launch

New Therapy – Rheumatology becoming formidable

The new Rheumatology Franchise grows to contribute significantly to specialty sales | Ortho portfolio basket, customer coverage augmentation underway

Multiple Initiatives expanding Prescriber & Patient base

Medico Marketing Pyramid | Digital Marketing Pyramid | Disease Education

Revenue/Cost optimization projects driving results

Revenue enhancement: New products, customers and markets| Cost optimization: Strict Opex control, Digitalization and AVD

Digitalisation & Innovation Agenda impacting key areas

“RPGServ” 3.0 grows to 10 versions with addition of Orthos; Technology upgrades| eQMS, eDMS, eLMS for product quality

Factories, R&D, Regulatory modernising up to support Frontend

Key Products Inhouse transfer| Modernization of both plants under execution | New Products development - WIP

Increasing Industry Interface and Performance Recognition

4 Industry Awards| Increased Traction in Investor meets and Media Interaction| RPG Best Corporate Performance award

“Happiness” Initiatives driving Happy Performance focused Culture

Happiness Score increase from 83% (FY21)→ 84% (FY22) → 87% (FY23)| Ranked #2 amongst RPG group companies

Headwinds Management

G C ompany

Diligent Management of Input Costs Increase

R?G LIFE SCIENCES

Digitalization Initiatives to Transform Business

Game Changer Customer Connect Initiative

Employee Connect Initiatives

• . -

9:27 ;

I!! Ill Ill

Ms. FalakJ lndal

My Service Requests

Logout

~ Scientific ~Update

~ Scientific ~ Support

C8 VID·19 Care

C8 VID·19 One Source

~ Scientific ~ Update

~ Scientific ~ Support

P<TIENT , EDUCATION MATERIAL

mil CONTACT l:iil us

PATIENT EDUCATION MATERIAL

Anytime, Anywhere Doctor Support Initiative

Industry First Initiative

2 .0

Digital Platform for comprehensive Salesforce Operations tracking: #Customer visits, customer engagement activities, sales performance analytics etc

a r,ca

HR Chatbot for quick resolution of queries related to HR process and company policies

A digital platform for Salesforce Grievance Redressal

Initiatives in Plant Operations

Range of Services

>80,000 Key Opinion Leaders

e-QMS: Digital platform to track all 6 quality parameters

e-DMS: Digital platform to manage all manufacturing/quality documents

e-LMS: Digital platform to track training sessions on CGMP

All above represent Illustrative list of the initiatives

An <l>» RPCi Company

e- Access: Retina scanning for machine access

R?G LIFE SCIENCES

People Initiatives to build Performance Culture with focus on Happiness

I Feel Valued

You Excel. We Applaud. Motivation continuum

I Live a Purposeful & Balanced Life

RPGLS Values Champions Living organizational values

An <l>» RPCi Company

I Love My Work

~ ~

RPGLS Heroes Outperformance recognition

High Happiness Quotient

I Feel Connected

RPGLS Happiness Forums Leadership Connect – Month & Quarter

I am Growing

We Skill. You Grow. Competency building continuum

• • 0

Akanksha Career development

I cherish our Culture

RPGLS Parivar Tyohar-Utsav Shrankhla Digital RPGLS family get- together

R?G LIFE SCIENCES

Initiatives for building a Performance Driven Culture: Glimpses

Skilling

Rewards & Recognition

Employee engagement: Parivar Tyohar Utsav

Employee Connect

An <l>» RPCi Company

Idea Generation

Happiness Initiative: Hello Happiness Forum Monthly Townhall for Connect, Recognition and Camaraderie: Glimpses

•• \..J

For Your Happiness @ RPCi L I FE SCIENCES

•

0 hello happiness

•

RPGLS Happiness Forum

\ J

Monthly Townhall for Connect, Recognition and Camaraderie

hello happiness Forum

Entertainment

· Rewards & Recognition --~

<le -==-

-~ Info sharing and Open-House

Long Service Awards

RPCLS Parivar A Happy Parivar

An <l>» RPCi Company

R?G LIFE SCIENCES

Happiness Initiative: Parivar Tyohar Utsav Shrankhla Virtual Celebration of Festivals with Families: Glimpses

•• \....,I

For Your Happiness @ R?G L I FE SCIENCES ii¢filt-ii¢3i ~

•

RPGLS Parivar Tyohar-Utsav Shrankhla

•

0 hello happiness

•

Virtual Celebration of Festivals with Families

" I loved these unique digital RPGLS-family get-togethers as these enabled entire RPGLS Parivaar to reach our colleagues ' homes, cities, and societies across the country and celebrate with their families ... Ganapati, Diwali, Hali, Govinda, Onam, Eid, Christmas ... all our festivals; hundreds of our family members joined from their own homes and had fun !! "

Yugal Sikri Managing Director

An <l>» RPCi Company

RPGLS PARIVAR - A HAPPY PARIVAR

R?G LIFE SCIENCES

Awards & Recognitions

An <l>» RPCi Company

R?G LIFE SCIENCES

RPG Life Sciences Bagged Top Awards from IDMA

Industry Recognition to RPG Life Sciences

Best Patent Award

Best Corporate Citizen Award

An <l>» RPCi Company

R?G LIFE SCIENCES

RPG Life Sciences Awarded with ‘Jamnalal Bajaj Award for Fair Business Practices’

Jamnalal Bajaj Award for Fair Business Practices (2021-22)

An <l>» RPCi Company

R?G LIFE SCIENCES

New Launch Naprosyn+ bags Brand Champion of the Year Award

1 SILVER IM- D I

RO "DLY .IPll , S, .

Naprosyn+

An <l>» RPCi Company

R?G LIFE SCIENCES

T H A N K

Y O U

An <l>» RPCi Company

R?G LIFE SCIENCES

← All Transcripts RPGLIFE Stock Page →

RPG Life Sciences Limited has informed the Exchange about Investor Presentation

Market Movers